Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258


An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Jemon K, Young V, Wilson M, McKee S, Ward V, Baird M, Young S, Hibma M.

PLoS One. 2013 Jun 14;8(6):e66866. doi: 10.1371/journal.pone.0066866. Print 2013.


Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.

Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880.


Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.

Li YL, Qiu XH, Shen C, Liu JN, Zhang J.

Oncol Rep. 2010 Nov;24(5):1323-9.


Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2008 Jan 1;14(1):169-77. doi: 10.1158/1078-0432.CCR-07-1881.


Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.

Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.

PLoS One. 2013 Sep 13;8(9):e71216. doi: 10.1371/journal.pone.0071216. eCollection 2013.


Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.

Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, Hung CF, Wu TC.

Cancer Immunol Immunother. 2013 Jul;62(7):1175-85. doi: 10.1007/s00262-013-1421-y. Epub 2013 Apr 25.


Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.

Seo SH, Jin HT, Park SH, Youn JI, Sung YC.

Vaccine. 2009 Sep 25;27(42):5906-12. doi: 10.1016/j.vaccine.2009.07.033. Epub 2009 Aug 3.


Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.

Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI, Hung CF.

Gene Ther. 2011 Mar;18(3):304-12. doi: 10.1038/gt.2010.151. Epub 2010 Oct 28.


Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.

Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.

Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136. Epub 2012 Sep 20.


Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.


A novel "priming-boosting" strategy for immune interventions in cervical cancer.

Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.

Mol Immunol. 2015 Apr;64(2):295-305. doi: 10.1016/j.molimm.2014.12.007. Epub 2015 Jan 6.


A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, Welters MJ, van Poelgeest MI, Melief CJ, Kenter GG, van der Burg SH.

Cancer Immunol Immunother. 2012 Sep;61(9):1485-92. doi: 10.1007/s00262-012-1292-7. Epub 2012 Jun 9.


A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.

Riezebos-Brilman A, Walczak M, Regts J, Rots MG, Kamps G, Dontje B, Haisma HY, Wilschut J, Daemen T.

Gene Ther. 2007 Dec;14(24):1695-704. Epub 2007 Oct 11.


A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.

Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P.

J Immunol. 2005 Dec 1;175(11):7297-302.


Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.

Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.

Cancer Immunol Immunother. 2004 Jul;53(7):642-50. Epub 2004 Feb 17.


Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.

Revaz V, Zurbriggen R, Moser C, Schiller JT, Ponci F, Bobst M, Nardelli-Haefliger D.

Antiviral Res. 2007 Oct;76(1):75-85. Epub 2007 Jun 19.


Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.

Zhao L, Liu B, Ren J, Feng J, Pang Z, Gao J, Zhang H, Tan W, Tian H, Ruan L.

Virol J. 2011 Jun 15;8:302. doi: 10.1186/1743-422X-8-302.


Therapeutic potential of protein and adjuvant vaccinations on tumour growth.

Gérard CM, Baudson N, Kraemer K, Bruck C, Garçon N, Paterson Y, Pan ZK, Pardoll D.

Vaccine. 2001 Mar 21;19(17-19):2583-9.


A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.

Bungener L, de Mare A, de Vries-Idema J, Sehr P, van der Zee A, Wilschut J, Daemen T.

Antivir Ther. 2006;11(6):717-27.


Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.

Hoffmann C, Stanke J, Kaufmann AM, Loddenkemper C, Schneider A, Cichon G.

J Immunother. 2010 Feb-Mar;33(2):136-45. doi: 10.1097/CJI.0b013e3181badc46.


Supplemental Content

Support Center